跳至主要内容
临床试验/CTRI/2024/06/068676
CTRI/2024/06/068676尚未招募2 期

A Phase II randomized controlled trial of Deuterium Depleted Water (DDW) administration or regular water in patients receiving neoadjuvant chemotherapy (NACT) for triple negative (TNBC) or HER2 positive breast cancer - NI

Tata Memorial Centre0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. All individuals above 18 years of age having histopathologicaly proven,
  • triple negative breast cancer (mTNBC) or Her-2 positive breast cancer who
  • are going to receive neo-adjuvant chemotherapy.
  • 2. Has a performance status of 0-3 on the Eastern Cooperative Oncology
  • Group (ECOG) Performance Scale.
  • 3. Willing and able to provide written informed consent and able to comply with
  • all trial procedures.

排除标准

  • 1. Patients who do not have histopathologicaly proven triple negative breast
  • cancer (mTNBC) or Her-2 positive breast cancer
  • 2. Patients who are not eligible for neo-adjuvant chemotherapy.

研究者

相似试验